Thijs H. Oude Munnink

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink et al. · Clinical Pharmacology & Therapeutics · 2010 · 792 citations

CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy

Urszula Domańska, Hetty Timmer‐Bosscha, Wouter B. Nagengast et al. · Neoplasia · 2012 · 185 citations · Full text

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting et al. · Cancer Research · 2013 · 118 citations · Full text

Bevacizumab-induced Normalization, Angiogenesis, Blood Vessel Normalization +15

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen et al. · Clinical Cancer Research · 2014 · 114 citations

⁸⁹Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922

Wouter B. Nagengast, Maarten A. de Korte, Thijs H. Oude Munnink et al. · Journal of Nuclear Medicine · 2010 · 112 citations · Full text